Dose-Response Relationship, Drug

"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The relationship between the dose of an administered drug and the response of the organism to the drug.

Descriptor ID	D004305
MeSH Number(s)	G07.690.773.875 G07.690.936.500
Concept/Terms	Dose-Response Relationship, Drug Dose-Response Relationship, Drug Dose-Response Relationships, Drug Drug Dose-Response Relationship Drug Dose-Response Relationships Relationship, Drug Dose-Response Relationships, Drug Dose-Response Dose Response Relationship, Drug

Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Dose-Response Relationship, Drug [G07.690.773.875]
Toxicological Phenomena [G07.690.936]
Dose-Response Relationship, Drug [G07.690.936.500]

Below are MeSH descriptors whose meaning is related to "Dose-Response Relationship, Drug".

Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".

Dose-Response Relationship, Drug
Hormesis
Lethal Dose 50

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.

Bar chart showing 725 publications over 30 distinct years, with a maximum of 49 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	8	8
1996	0	12	12
1997	0	8	8
1998	0	17	17
1999	0	12	12
2000	0	12	12
2001	0	15	15
2002	0	32	32
2003	0	37	37
2004	0	32	32
2005	0	49	49
2006	1	41	42
2007	0	38	38
2008	1	40	41
2009	0	38	38
2010	0	38	38
2011	0	36	36
2012	0	30	30
2013	0	27	27
2014	0	29	29
2015	0	29	29
2016	1	32	33
2017	1	22	23
2018	0	24	24
2019	0	22	22
2020	0	15	15
2021	0	10	10
2022	0	1	1
2024	1	5	6
2025	0	9	9

Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.

Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats CJ, Fifer MA, Sherrid MV, Solomon SD, Watkins H, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Maron MS, Masri A. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. JACC Heart Fail. 2025 Aug; 13(8):102496.

View in: PubMed
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2203-2214.

View in: PubMed
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.

View in: PubMed
Greenberg RG, Lang J, Smith PB, Shekhawat P, Courtney SE, Hudak ML, Moya F, Iyengar A, Eldemerdash A, Bloom B, Go M, Hanna M, Rhein L, Aliaga S, Lewis T, Febre A, Kiefer AS, Bhatt-Mehta V, Khoury JA, Selewski D, Anand R, Martz K, Payne EH, Zimmerman KO, Benjamin DK, Laughon M. Furosemide Safety in Preterm Infants at Risk for Bronchopulmonary Dysplasia: A Randomized Clinical Trial. J Pediatr. 2025 Aug; 283:114629.

View in: PubMed
Oliveto AH, McGaugh J, Chopra MP, Thostenson J, Mancino MJ. A randomized clinical trial of disulfiram at higher doses for the treatment of cocaine use disorder among methadone-stabilized patients. J Psychiatr Res. 2025 Jun; 186:387-395.

View in: PubMed
Sang-Ngern M, Fukuchi A, Kondratyuk TP, Park EJ, Simmons CJ, Wall MM, Lorch SE, Pezzuto JM, Chang LC. Biologically active withanolides from Physalis peruviana. Pharm Biol. 2025 Dec; 63(1):334-343.

View in: PubMed
Nunes AP, Jung H, Yuan Y, Baek J, Pawasauskas J, Hume AL, Liu SH, Lapane KL. Comparative Safety of Short-Acting Opioid Dose Escalation and Long-Acting Opioid Initiation in Nursing Home Residents. J Am Geriatr Soc. 2025 May; 73(5):1517-1527.

View in: PubMed
Balis FM, Rieger E, Bunin NJ, Gardiner J, Shaw LM, Olson TS, Milone MC. New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis. Cancer Chemother Pharmacol. 2025 Feb 11; 95(1):32.

View in: PubMed
Banerjee R, Sexton R, Cowan AJ, Rosenberg AS, Ailawadhi S, Rajkumar SV, Kumar S, Dispenzieri A, Lonial S, Durie BGM, Richardson PG, Usmani SZ, Hoering A, Orlowski RZ. Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 2025 01 02; 145(1):75-84.

View in: PubMed
Bisht P, Bhattacharya A, Pal A, Singh R, Verma SK. Design and synthesis of novel 3,7-dihydro-1H-purine-2,6-diones as DPP-4 inhibitors: An in silico, in vitro and in vivo approach. Eur J Med Chem. 2025 Feb 05; 283:117160.

View in: PubMed

People

Explore

Similar Concepts

Top Journals